Pulmonx Corp 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Pulmonx Corp (Nasdaq: LUNG) on August 2, 2021, reporting events occurring on July 29, 2021. The company is an emerging growth company incorporated in Delaware.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
The Board of Directors appointed two new Class I directors effective July 29, 2021:
- Ms. Alissa Hsu Lynch: Appointed to the Audit Committee.
- Ms. Tiffany Sullivan: Appointed to the Nominating and Corporate Governance Committee.
Both directors serve until the 2024 annual meeting of stockholders. No prior arrangement or understanding existed regarding these appointments.
Compensation and Governance Details
Compensation for the new directors follows the Non-Employee Director Compensation Policy:
- Annual Cash Compensation: $40,000 for Board service.
- Committee Fees: $10,000 for Ms. Lynch (Audit Committee); $5,000 for Ms. Sullivan (Nominating and Corporate Governance Committee).
- Initial Equity Grant: Restricted stock units (RSUs) with a fair value of $180,000, vesting one-third annually over three years.
- Future Equity Grants: Annual RSU grants with a fair value of $120,000 commencing after the 2022 annual meeting, vesting 100% within one year or by the subsequent annual meeting.
Both directors entered into standard indemnification agreements.
Key Facts for Investor Verification
- Verify the independence status of Ms. Lynch and Ms. Sullivan in the company's proxy statement.
- Confirm the total number of authorized director seats to assess the impact of these appointments on board composition.
- Review the specific vesting schedules and performance conditions (if any) attached to the $180,000 initial RSU grants.
- Check for any related party transactions or conflicts of interest disclosed in subsequent filings.